| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1721d75f5bf603447ec5a26b5c1c0be0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-53 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate |
2009-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bc42edf71070a25228eaf71de15d918
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f0b040b28e93dcca0976d16021d7401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f1362a0a49476e261b43e2337031f0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_285a635260c75f26cc101f980e629e75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_314d1af79bc0be0ee3efdbf033daa343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba1f8c9fd9e1ebb6e36ad8f0d227fd48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92a1ebd7064af54cda6d3ac990b1955e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c64da4288b31a4644dfc0dea42f00447 |
| publicationDate |
2009-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009311716-A1 |
| titleOfInvention |
METHODS TO TREAT OR PREVENT HORMONE-RESISTANT PROSTATE CANCER USING siRNA SPECIFIC FOR PROTOCADHERIN-PC, OR OTHER INHIBITORS OF PROTOCADHERIN-PC EXPRESSION OR ACTIVITY |
| abstract |
The invention is directed to compounds and methods for treating or preventing hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity, including antisense oligonucleotides and antibodies. The invention also provides for the use of protocadherin-PC as an in vivo prostate cancer biomarker, and includes a kit for detecting prostate cancer in biological samples. Also covered by the invention is a transgenic non-human mammal engineered to overexpress protocadherin-PC specifically in the prostate. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9175291-B2 |
| priorityDate |
2005-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |